With the PTAB facing questions over its authority and even constitutionality, life sciences companies seem to be faring well, at least compared to other industries, as LSIPR finds out.
The Patent Trial and Appeal Board (PTAB) is facing major scrutiny as big pharma companies look at ways to avoid inter partes reviews (IPRs) and the US Supreme Court looks into the very constitutionality of the procedure.
Former President Barack Obama passed the America Invents Act into law in September 2011, introducing new procedures for challenging patent validity at the US Patent and Trademark Office.
Fast-forward one year and the IPR procedure became available, allowing any person to challenge a patent before a panel of administrative judges at the PTAB.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Patent Trial and Appeal Board, PTAB, PTAb test, Pozen’s Vimovo, naproxen and esomeprazole, osteoarthritis , Allergan, patents, biopharma, IPRs, pharma